scispace - formally typeset
Open AccessJournal ArticleDOI

Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination.

TLDR
A 90% reduction in TB-related mortality and an 80% decline in TB incidence within 2030 as well as the abolition of catastrophic expenditures for TB-affected people are the main targets of this strategy.
Abstract
Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide, accounting for about 9.6 million new cases and 1.5 million deaths annually. The poorest and socially excluded groups carry the largest burden of disease, which makes it essential to properly address the social determinants of health through poverty reduction measures and targeted interventions on high-risk populations. The spread of multidrug-resistance TB requires special attention and highlights the need to foster research on TB diagnostics, new drugs and vaccines. Although many advances have been made in the fight against TB over the last twenty years, a lot is still needed to achieve global elimination. The new end-TB strategy that was first launched in 2014 by the World Health Organization, is fully in line with the seventeen Sustainable Development Goals that came into effect since January 2016 and sets ambitious goals for the post-2015 agenda. A 90% reduction in TB-related mortality and an 80% decline in TB incidence within 2030 as well as the abolition of catastrophic expenditures for TB-affected people are the main targets of this strategy. Strong government commitment and adequate financing from all countries together with community engagement and appropriate investments in research are necessary in order to reach these objectives.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis.

TL;DR: It is demonstrated how long term increases in TB burden could be averted in the short term through supplementary “catch-up” TB case detection and treatment, once restrictions are eased.
Journal ArticleDOI

Recent updates on drug resistance in Mycobacterium tuberculosis

TL;DR: The aim of this review is to provide recent updates on drug resistance mechanisms, newly developed/repurposed anti‐TB agents in pipeline and international recommendations to manage MDR‐TB, based on recent literature and WHO guidelines and aims to facilitate better understanding of drug resistance for effective TB therapy and clinical management.
Journal ArticleDOI

Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis

TL;DR: It is discovered that the combination of cysteine or other small thiols with either isoniazid or rifampicin prevents the formation of drug-tolerant and drug-resistant cells in Mtb cultures, leading to mycobacterial cell death.
Journal ArticleDOI

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.

TL;DR: Data from controlled trials, national registries of biologics, and postmarketing surveillance show that the risk of TB reactivation in patients receiving non-anti-TNF-targeted biologicics is negligible, raising the question whether the screening procedures for LTBI would be necessary.
References
More filters
Journal ArticleDOI

WHO's new End TB Strategy

TL;DR: Ending the tuberculosis epidemic in high-incidence countries needs a similar approach that guarantees access to high-quality tuberculosis care and prevention to all while simul taneously addressing the social determinants of tuberculosis.
Journal ArticleDOI

Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

TL;DR: Host-directed therapies are now being developed to refocus the anti-Mycobacterium tuberculosis-directed immune responses towards the host; a strategy that could be especially beneficial for patients with multidrug- resistant tuberculosis or extensively drug-resistant tuberculosis.
Related Papers (5)